The stock of Adma Biologics Inc (NASDAQ: ADMA) has increased by 2.63 when compared to last closing price of 19.04.Despite this, the company has seen a loss of -13.08% in its stock price over the last five trading days. prnewswire.com reported 2024-11-18 that NEW YORK, Nov. 18, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Is It Worth Investing in Adma Biologics Inc (NASDAQ: ADMA) Right Now?
The price-to-earnings ratio for Adma Biologics Inc (NASDAQ: ADMA) is above average at 70.72x, Company’s 36-month beta value is 0.67.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ADMA is 228.41M, and currently, short sellers hold a 6.65% ratio of that floaft. The average trading volume of ADMA on November 19, 2024 was 5.16M shares.
ADMA’s Market Performance
The stock of Adma Biologics Inc (ADMA) has seen a -13.08% decrease in the past week, with a 23.83% rise in the past month, and a 8.98% gain in the past quarter. The volatility ratio for the week is 4.94%, and the volatility levels for the past 30 days are at 5.09% for ADMA. The simple moving average for the last 20 days is 4.67% for ADMA’s stock, with a simple moving average of 63.71% for the last 200 days.
Analysts’ Opinion of ADMA
Many brokerage firms have already submitted their reports for ADMA stocks, with Raymond James repeating the rating for ADMA by listing it as a “Strong Buy.” The predicted price for ADMA in the upcoming period, according to Raymond James is $5 based on the research report published on July 19, 2023 of the previous year 2023.
Mizuho, on the other hand, stated in their research note that they expect to see ADMA reach a price target of $5. The rating they have provided for ADMA stocks is “Buy” according to the report published on October 13th, 2022.
Raymond James gave a rating of “Strong Buy” to ADMA, setting the target price at $5 in the report published on November 11th of the previous year.
ADMA Trading at 5.25% from the 50-Day Moving Average
After a stumble in the market that brought ADMA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -17.34% of loss for the given period.
Volatility was left at 5.09%, however, over the last 30 days, the volatility rate increased by 4.94%, as shares surge +25.10% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +6.31% upper at present.
During the last 5 trading sessions, ADMA fell by -13.08%, which changed the moving average for the period of 200-days by +273.61% in comparison to the 20-day moving average, which settled at $18.67. In addition, Adma Biologics Inc saw 332.30% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ADMA starting from Guiheen Lawrence P., who sale 9,000 shares at the price of $18.47 back on Sep 09 ’24. After this action, Guiheen Lawrence P. now owns 153,941 shares of Adma Biologics Inc, valued at $166,189 using the latest closing price.
Guiheen Lawrence P., the Director of Adma Biologics Inc, proposed sale 9,000 shares at $16.26 during a trade that took place back on Sep 09 ’24, which means that Guiheen Lawrence P. is holding shares at $146,340 based on the most recent closing price.
Stock Fundamentals for ADMA
Current profitability levels for the company are sitting at:
- 0.3 for the present operating margin
- 0.49 for the gross margin
The net margin for Adma Biologics Inc stands at 0.18. The total capital return value is set at 0.33. Equity return is now at value 35.55, with 18.42 for asset returns.
Based on Adma Biologics Inc (ADMA), the company’s capital structure generated 0.3 points at debt to capital in total, while cash flow to debt ratio is standing at 0.85. The debt to equity ratio resting at 0.44. The interest coverage ratio of the stock is 6.65.
Currently, EBITDA for the company is 5.12 million with net debt to EBITDA at 0.25. When we switch over and look at the enterprise to sales, we see a ratio of 12.13. The receivables turnover for the company is 7.63for trailing twelve months and the total asset turnover is 0.98. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.09.
Conclusion
In a nutshell, Adma Biologics Inc (ADMA) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
